Amphastar reports Q3 revenue growth to $207.6M with GAAP net income of $37.8M, driven by strong sales of key products.

Amphastar Pharmaceuticals posted $207.6 million in net revenues for Q3 2026, an 8% increase from the previous year, driven by record sales of BAQSIMI and Primatene MIST. GAAP net income rose to $37.8 million, or $0.87 per share, while adjusted non-GAAP net income was $49.3 million, or $1.14 per share. The company continues to invest in manufacturing and pipeline development, including complex generics and biosimilars, and announced a $50 million increase to its share buyback program. Amphastar remains focused on long-term growth and operational strength amid ongoing FDA remediation efforts at a subsidiary.

Amphastar Pharmaceuticals shares trade at USD 27.59 on Pluang as of Nov 06, 2026 04:11 WIB, down 1.53% for the day. The stock's market cap stands at $1.19 billion with a 52-week high of $29.40. Investors hold the stock for an average of 18 days on the platform.